APLS - Apellis Pharmaceuticals Inc

APLS - Apellis Pharmaceuticals Inc

https://apellis.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 5 days ago • score: 0.30

WALTHAM, Mass., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that management will participate in webcast fireside chats at the following investor conferences: ...

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - Apellis Pharmaceuticals ( NASDAQ:APLS )

Benzinga • 2 weeks, 5 days ago • score: 0.26

WALTHAM, Mass., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Date/Time: Wednesday, September 3, 2025 at 8:45 a.m. ET

FDA Approves Apellis' Empaveli, Marks Key Milestone - Apellis Pharmaceuticals ( NASDAQ:APLS )

Benzinga • 1 month, 2 weeks ago • score: 0.23

Empaveli cut proteinuria by 68% in C3G and IC-MPGN patients in a six-month trial. 71% of patients on Empaveli had complete clearance of C3 deposits. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - Apellis Pharmaceuticals ( NASDAQ:APLS )

Benzinga • 1 month, 3 weeks ago • score: 0.27

WALTHAM, Mass., July 24, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

GlobeNewswire • 1 month, 3 weeks ago • score: 0.27

WALTHAM, Mass., July 24, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.

52W High

$41.94

52W Low

$16.10

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.72

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

46.30

EV/EBITDA (<8 favorable)

-12.12

EV/Revenue (<3 favorable)

4.84

P/S (TTM) (<3 favorable)

4.71

P/B (<3 favorable)

22.73

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

13.69%

Institutions (25–75% balanced)

105.78%

Shares Outstanding

126,290,000

Float

78,384,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

754,649,000

Gross Profit (TTM)

313,891,000

EPS (TTM)

-1.83

Profit Margin (>10% good)

-0.30%

Operating Margin (TTM) (higher better)

-0.19%

ROE (TTM) (>15% strong)

-1.09%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.11

Momentum

Bearish momentum

Value

0.4997

Previous

0.7792

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025